{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:11:44Z","timestamp":1787901104899,"version":"build-2784847793"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,2,16]],"date-time":"2014-02-16T00:00:00Z","timestamp":1392508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/2.0"},{"start":{"date-parts":[[2014,2,16]],"date-time":"2014-02-16T00:00:00Z","timestamp":1392508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with melanoma brain metastases have a poor prognosis and historically have been excluded from clinical trials. The Expanded Access Program (EAP) provided an opportunity to evaluate the feasibility of ipilimumab (3\u00a0mg\/kg every 3\u00a0weeks for four doses) in patients with stage 3 (unresectable) or 4 melanoma and asymptomatic brain metastases, who had failed or did not tolerate previous treatments and had no other therapeutic option available. Tumor assessments were conducted at baseline and week 12 using immune-related response criteria and patients were monitored for adverse events (AEs). Of 855 patients participating in the EAP in Italy, 146 had asymptomatic brain metastases. With a median follow-up of 4\u00a0months, the global disease control rate was 27\u00a0%, including 4 patients with a complete response and 13 with a partial response. Median progression-free survival and overall survival were 2.8 and 4.3\u00a0months, respectively and approximately one-fifth of patients were alive 1\u00a0year after starting ipilimumab. In total, 29\u00a0% of patients reported a treatment-related AE of any grade, which were grade 3\/4 in 6\u00a0% of patients. AEs were generally reversible with treatment as per protocol-specific guidelines. Ipilimumab shows durable benefits in some patients with advanced melanoma metastatic to the brain, with safety results consistent with those previously reported in clinical trials.<\/jats:p>","DOI":"10.1007\/s11060-014-1400-y","type":"journal-article","created":{"date-parts":[[2014,2,17]],"date-time":"2014-02-17T12:32:16Z","timestamp":1392640336000},"page":"109-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases"],"prefix":"10.1007","volume":"118","author":[{"given":"Paola","family":"Queirolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Scoppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Di Guardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cognetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Ferraresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ridolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Guidoboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Pigozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna","family":"Chiarion Sileni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,16]]},"reference":[{"key":"1400_CR1","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","volume":"22","author":"KM Fife","year":"2004","unstructured":"Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, Harman R, Petersen-Schaefer K, Zacest AC, Besser M, Milton GW, McCarthy WH, Thompson JF (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22:1293\u20131300","journal-title":"J Clin Oncol"},{"key":"1400_CR2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/107327480901600307","volume":"16","author":"AE Sloan","year":"2009","unstructured":"Sloan AE, Nock CJ, Einstein DB (2009) Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control 16:248\u2013255","journal-title":"Cancer Control"},{"key":"1400_CR3","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/cncr.22905","volume":"110","author":"M Majer","year":"2007","unstructured":"Majer M, Jensen RL, Shrieve DC, Watson GA, Wang M, Leachman SA, Boucher KM, Samlowski WE (2007) Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Cancer 110:1329\u20131337","journal-title":"Cancer"},{"key":"1400_CR4","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/sj.bjc.6605622","volume":"102","author":"M Staudt","year":"2010","unstructured":"Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, Tatagiba M, Brossart P, Garbe C (2010) Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 102:1213\u20131218. doi:10.1038\/sj.bjc.6605622","journal-title":"Br J Cancer"},{"key":"1400_CR5","doi-asserted-by":"publisher","unstructured":"Bhangoo SS, Linskey ME, Kalkanis SN, American Association of Neurologic Surgeons (AANS), Congress of Neurologic Surgeons (CNS) (2011) Evidence-based guidelines for the management of brain metastases. Neurosurg Clin N Am 22:97\u2013104, viii. doi:10.1016\/j.nec.2010.09.001","DOI":"10.1016\/j.nec.2010.09.001"},{"key":"1400_CR6","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.4065\/78.12.1529","volume":"78","author":"RR McWilliams","year":"2003","unstructured":"McWilliams RR, Brown PD, Buckner JC, Link MJ, Markovic SN (2003) Treatment of brain metastases from melanoma. Mayo Clin Proc 78:1529\u20131536","journal-title":"Mayo Clin Proc"},{"key":"1400_CR7","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1200\/JCO.2006.10.0677","volume":"25","author":"ER Gerstner","year":"2007","unstructured":"Gerstner ER, Fine RL (2007) Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 25:2306\u20132312","journal-title":"J Clin Oncol"},{"key":"1400_CR8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/cncr.24735","volume":"116","author":"K Yonemori","year":"2010","unstructured":"Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, Narita Y, Shibui S, Fujiwara Y (2010) Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2\/neu-positive breast cancer. Cancer 116:302\u2013308. doi:10.1002\/cncr.24735","journal-title":"Cancer"},{"issue":"9 Suppl","key":"1400_CR9","first-page":"1125P","volume":"23","author":"R Dummer","year":"2012","unstructured":"Dummer R, Goldinger S, Turtschi C, Eggmann N, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Rinderknecht JD (2012) Open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with symptomatic brain metastases. Ann Oncol 23(9 Suppl):1125P","journal-title":"Ann Oncol"},{"key":"1400_CR10","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","volume":"13","author":"GV Long","year":"2012","unstructured":"Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087\u20131095. doi:10.1016\/S1470-2045(12)70431-X","journal-title":"Lancet Oncol"},{"key":"1400_CR11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1053\/j.seminoncol.2010.09.015","volume":"37","author":"A Hoos","year":"2010","unstructured":"Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R (2010) Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 37:533\u2013546. doi:10.1053\/j.seminoncol.2010.09.015","journal-title":"Semin Oncol"},{"key":"1400_CR12","unstructured":"YERVOY\u2122 Summary of Product Characteristics. http:\/\/www.medicines.org.uk\/emc\/medicine\/24779\/SPC\/yervoy%205%20mg~ml%20concentrate%20for%20solution%20for%20infusion\/#INDICATIONS. Accessed on 6 Jan 2014"},{"key":"1400_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb\u00e9 C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723. doi:10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"1400_CR14","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O\u2019Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517\u20132526. doi:10.1056\/NEJMoa1104621","journal-title":"N Engl J Med"},{"issue":"9 Suppl","key":"1400_CR15","first-page":"1116PD","volume":"23","author":"C Lebbe","year":"2012","unstructured":"Lebbe C, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, Opatt McDowell D, Cykowski L, McHenry MB, Wolchok JD (2012) Five-year survival rates for patients with metastatic melanoma treated with ipilimumab in phase II trials. Ann Oncol 23(9 Suppl):1116PD","journal-title":"Ann Oncol"},{"key":"1400_CR16","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-11-1823","volume":"18","author":"PA Prieto","year":"2012","unstructured":"Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ (2012) CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18:2039\u20132047. doi:10.1158\/1078-0432.CCR-11-1823","journal-title":"Clin Cancer Res"},{"issue":"15 Suppl","key":"1400_CR17","doi-asserted-by":"crossref","first-page":"8583","DOI":"10.1200\/jco.2011.29.15_suppl.8583","volume":"29","author":"RA Ibrahim","year":"2011","unstructured":"Ibrahim RA, Berman DM, DePril V, Humphrey RW, Chen T, Messina M, Chin KM, Liu HY, Bielefield M, Hoos A (2011) Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J Clin Oncol 29(15 Suppl):8583","journal-title":"J Clin Oncol"},{"key":"1400_CR18","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","volume":"12","author":"J Weber","year":"2007","unstructured":"Weber J (2007) Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12:864\u2013872","journal-title":"Oncologist"},{"key":"1400_CR19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13:459\u2013465. doi:10.1016\/S1470-2045(12)70090-6","journal-title":"Lancet Oncol"},{"key":"1400_CR20","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S1470-2045(12)70324-8","volume":"13","author":"AM Di Giacomo","year":"2012","unstructured":"Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, Fonsatti E, Annesi D, Queirolo P, Testori A, Ridolfi R, Parmiani G, Maio M (2012) Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 13:879\u2013886. doi:10.1016\/S1470-2045(12)70324-8","journal-title":"Lancet Oncol"},{"key":"1400_CR21","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/CMR.0b013e32834d3d88","volume":"21","author":"JS Weber","year":"2011","unstructured":"Weber JS, Amin A, Minor D, Siegel J, Berman D, O\u2019Day SJ (2011) Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 21:530\u2013534. doi:10.1097\/CMR.0b013e32834d3d88","journal-title":"Melanoma Res"},{"issue":"8 Suppl","key":"1400_CR22","first-page":"13240","volume":"21","author":"C Lebbe","year":"2010","unstructured":"Lebbe C, McDermott DF, Robert C, Lorigan P, Ottensmeier CH, Wolchok J, Garbe C, Messina M, Hoos A, Weber JS (2010) Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: subgroup analyses from a phase III trial. Ann Oncol 21(8 Suppl):13240","journal-title":"Ann Oncol"},{"issue":"15 Suppl","key":"1400_CR23","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1200\/jco.2011.29.15_suppl.8581","volume":"29","author":"K Heller","year":"2011","unstructured":"Heller K, Pavlick AC, Hodi FS, Thompson JA, Margolin KA, Lawrence DP, McDermott DF, Samlowski WE, Michener T, Karasarides M (2011) Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. J Clin Oncol 29(15 Suppl):8581","journal-title":"J Clin Oncol"},{"key":"1400_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2045-8118-8-4","volume":"8","author":"B Engelhardt","year":"2011","unstructured":"Engelhardt B, Coisne C (2011) Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS 8:4. doi:10.1186\/2045-8118-8-4","journal-title":"Fluids Barriers CNS"},{"key":"1400_CR25","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1172\/JCI41911","volume":"120","author":"EH Wilson","year":"2010","unstructured":"Wilson EH, Weninger W, Hunter CA (2010) Trafficking of immune cells in the central nervous system. J Clin Invest 120:1368\u20131379. doi:10.1172\/JCI41911","journal-title":"J Clin Invest"},{"issue":"9 Suppl","key":"1400_CR26","first-page":"1132P","volume":"23","author":"P Queirolo","year":"2012","unstructured":"Queirolo P, Simeone E, De Galitiis F, Di Guardo L, Di Giacomo AM, Marconcini R, Ferraresi V, De Rosa F, Guida M, Stragliotto S (2012) Efficacy and safety data from patients with advanced melanoma and brain metastases participating in the European ipilimumab Expanded Access Programme in Italy. Ann Oncol 23(9 Suppl):1132P","journal-title":"Ann Oncol"},{"key":"1400_CR27","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412\u20137420. doi:10.1158\/1078-0432.CCR-09-1624","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1400_CR28","first-page":"868","volume":"25","author":"D Lawrence","year":"2012","unstructured":"Lawrence D, McDermott D, Hamid O, Weber JS, Wolchok J, Richards J, Minor D, Pavlick A, Sznol M, Hwu P, Urba W, Amin A, Bennett K, Michener T, Balogh A, Hodi F (2012) Treatment of patients with stage III or IV melanoma on an ipilimumab Expanded Access Program: results for 3\u00a0mg\/kg cohort. Pigment Cell Melanoma Res 25(6):868","journal-title":"Pigment Cell Melanoma Res"},{"issue":"9 Suppl","key":"1400_CR29","first-page":"1127P","volume":"23","author":"M Maio","year":"2012","unstructured":"Maio M, Bondarenko I, Robert C, Thomas L, Garbe C, Testori A, Francis S, Chin K, Wolchok J (2012) Four-year survival update for metastatic melanoma patients treated with ipilimumab plus dacarbazine in phase 3 study CA184-024. Ann Oncol 23(9 Suppl):1127P","journal-title":"Ann Oncol"},{"key":"1400_CR30","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","volume":"15","author":"J Weber","year":"2009","unstructured":"Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O\u2019Day SJ (2009) A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15:5591\u20135598. doi:10.1158\/1078-0432.CCR-09-1024","journal-title":"Clin Cancer Res"},{"key":"1400_CR31","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1089\/cbr.2010.0865","volume":"25","author":"A Tarhini","year":"2010","unstructured":"Tarhini A, Lo E, Minor DR (2010) Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm 25:601\u2013613. doi:10.1089\/cbr 2010.0865","journal-title":"Cancer Biother Radiopharm"},{"key":"1400_CR32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/01.cji.0000177999.95831.7b","volume":"28","author":"CS Hinrichs","year":"2005","unstructured":"Hinrichs CS, Palmer DC, Rosenberg SA, Restifo NP (2005) Glucocorticoids do not inhibit antitumor activity of activated CD8\u00a0+\u00a0T cells. J Immunother 28:517\u2013524","journal-title":"J Immunother"},{"issue":"15 Suppl","key":"1400_CR33","doi-asserted-by":"crossref","first-page":"8569","DOI":"10.1200\/jco.2012.30.15_suppl.8569","volume":"30","author":"A Ackerman","year":"2012","unstructured":"Ackerman A, McDermott DF, Lawrence DP, Gunturi A, Flaherty KT, Giobbie-Hurder A, Hodi FS, Ibrahim N, Atkins MB, Cho DC, Sullivan RJ (2012) Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib. J Clin Oncol 30(15 Suppl):8569","journal-title":"J Clin Oncol"},{"key":"1400_CR34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1479-5876-10-107","volume":"10","author":"PA Ascierto","year":"2012","unstructured":"Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N (2012) Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med 10:107. doi:10.1186\/1479-5876-10-107","journal-title":"J Transl Med"},{"issue":"9 Suppl","key":"1400_CR35","first-page":"1128P","volume":"23","author":"PA Ascierto","year":"2012","unstructured":"Ascierto PA, Chiarion Sileni V, Del Vecchio M, Altomonte M, De Galitiis F, Ridolfi L, Cognetti F, Testori A, Bernengo MG, Queirolo P (2012) The European ipilimumab Expanded Access Programme: efficacy and safety data from the Italian cohort of patients with pretreated, advanced melanoma. Ann Oncol 23(9 Suppl):1128P","journal-title":"Ann Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-014-1400-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-014-1400-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-014-1400-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-014-1400-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T23:00:00Z","timestamp":1630537200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-014-1400-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,16]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["1400"],"URL":"https:\/\/doi.org\/10.1007\/s11060-014-1400-y","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718278853.793491438","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,16]]},"assertion":[{"value":"3 October 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}